Alvaro Morales | Academic Influence

Alvaro Morales 's AcademicInfluence.com Rankings

Alvaro Morales

Computer Science

#6764

World Rank

#7129

Historical Rank

Machine Learning

#2462

World Rank

#2494

Historical Rank

Artificial Intelligence

#2746

World Rank

#2789

Historical Rank

Database

#3850

World Rank

#4006

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Alvaro Morales 's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Alvaro Morales Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Dr. Alvaro Morales, MD, FRCSC is a Colombian-Canadian urologist, surgeon and Member of the Order of Canada who is noted for his work in the fields of cancer research and testosterone deficiency. He is particularly known for his pioneering work using Bacillus Calmette–Guérin to treat bladder cancer, the first proven immunotherapy for cancer. A 2018 article in the Canadian Urological Association Journal said Morales' cancer research "changed the course of urology" and described him as a "living legend."

(See a Problem?)

Alvaro Morales 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. (1992) (694)
INTRACAVITARY BACILLUS CALMETTE‐GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER TUMORS (1976) (584)
Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction (1998) (481)
Summary of the recommendations on sexual dysfunctions in men. (2004) (327)
History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. (2008) (308)
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. (2007) (277)
Investigation, treatment and monitoring of late-onset hypogonadism in males. Official Recommendations of ISSAM (2002) (257)
Andropause: a misnomer for a true clinical entity. (2000) (251)
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976. (2002) (231)
DOUBLE-BLIND TRIAL OF YOHIMBINE IN TREATMENT OF PSYCHOGENIC IMPOTENCE (1987) (229)
Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. (1997) (193)
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. (1976) (191)
Recovery of erectile function by the oral administration of apomorphine. (1995) (181)
Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. (1987) (175)
Endocrine aspects of sexual dysfunction in men. (2004) (157)
Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. (1984) (144)
A new era of testosterone and prostate cancer: from physiology to clinical implications. (2014) (144)
Bacillus Calmette‐Guérin immunotherapy for genitourinary cancer (2013) (134)
The characterization of a bio-assay of erectile function in a rat model. (1991) (126)
A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. (1997) (123)
Rapid detection of bladder cancer: a comparative study of point of care tests. (1997) (122)
Testosterone and prostate cancer: revisiting old paradigms. (2009) (118)
Testosterone Deficiency Syndrome (TDS) needs to be named appropriately--the importance of accurate terminology. (2006) (110)
Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. (1996) (109)
Nonhormonal pharmacological treatment of organic impotence. (1982) (109)
Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. (1989) (105)
Androgen replacement therapy and prostate safety. (2002) (100)
Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations (2009) (100)
Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. (1996) (92)
Bacterial biofilm in persistent penile prosthesis-associated infection. (1986) (92)
Absorption of alkalized intravesical lidocaine in normal and inflamed bladders: a simple method for improving bladder anesthesia. (2001) (88)
The role of nocturnal penile tumescence monitoring in the diagnosis of impotence: a review. (1990) (87)
Dietary patterns and risk of prostate cancer in Ontario, Canada (2005) (86)
Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. (1984) (80)
Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. (1992) (80)
A review of the current status of topical treatments for premature ejaculation (2007) (79)
Yohimbine in erectile dysfunction: the facts (2000) (77)
Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline (2015) (77)
Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. (1981) (77)
Oral androgens in the treatment of hypogonadal impotent men. (1994) (74)
Cimetidine in the treatment of interstitial cystitis. (1994) (73)
Topical nitroglycerin: a potential treatment for impotence. (1989) (73)
Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. (2015) (72)
Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. (2001) (71)
Prevalence and significance of tobacco smoking in impotence. (1986) (68)
Hormonal erectile dysfunction. Evaluation and management. (2001) (67)
Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney. (1976) (66)
Oral and topical treatment of erectile dysfunction. Present and future. (1995) (65)
Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. (1996) (63)
Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells (1999) (62)
Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. (2009) (61)
Topical lidocaine–prilocaine spray for the treatment of premature ejaculation: a proof of concept study (2003) (61)
Andropause (or symptomatic late-onset hypogonadism): facts, fiction and controversies (2004) (59)
Adding to the controversy: Pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry (2007) (56)
Aspiration and sclerotherapy versus hydrocelectomy for treatment of hydroceles. (2003) (55)
Carcinoma of the prostate: a critical look at staging. (1977) (55)
Adherence of gram-negative uropathogens to human uroepithelial cells. (1983) (52)
Topical glyceryltrinitrate causes measurable penile arterial dilation in impotent men. (1990) (52)
A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel (2013) (52)
An objective look at acid phosphatase determinations: a comparison of biochemical and immunological methods. (1979) (51)
Surgical treatment of penile veno-occlusive dysfunction: is it justified? (1996) (50)
The reliability of clinical and biochemical assessment in symptomatic late‐onset hypogonadism: can a case be made for a 3‐month therapeutic trial? (2004) (50)
Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeability barrier. (1998) (46)
A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative (1997) (46)
Androgen deficiency in the aging male: when, who, and how to investigate and treat. (2002) (44)
TEMPE: Topical Eutectic-Like Mixture for Premature Ejaculation (2008) (43)
The unreliability of nocturnal penile tumescence recording as an outcome measurement in the treatment of organic impotence. (1986) (43)
Biofeedback: a noninvasive treatment for incontinence after radical prostatectomy. (1996) (43)
The Quality of Life During Intravesical Bacillus Calmette-Guerin Therapy (1996) (42)
Diagnostic significance of penile erections during sleep. (1982) (40)
Beyond a Simple Anesthetic Effect: Lidocaine in the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome. (2015) (39)
Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency (2009) (38)
Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry (2011) (38)
A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians. (2013) (37)
The pharmacokinetics of yohimbine in man (2006) (36)
Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges. (2010) (35)
Immunotherapy for superficial bladder cancer. A developmental and clinical overview. (1992) (34)
Treatment of carcinoma in situ of the bladder with BCG (1980) (34)
The prevalence and influence of significant psychiatric abnormalities in men undergoing comprehensive management of organic erectile dysfunction (2000) (34)
The treatment of Peyronie's disease with parathyroid hormone. (1975) (34)
Unreliability of nocturnal penile tumescence recording and MMPI profiles in assessment of impotence. (1981) (34)
Hormones in the treatment of metastatic renal cancer. (1975) (34)
Oral and transcutaneous pharmacologic agents in the treatment of impotence. (1988) (33)
Vascular control mechanisms in penile erection: phylogeny and the inevitability of multiple and overlapping systems (1997) (33)
Severe erectile dysfunction is a marker for hyperprolactinemia (2001) (32)
BCG induced murine peritoneal exudate cells: cytotoxic activity against a syngeneic bladder tumor cell line. (1982) (32)
The long and tortuous history of the discovery of testosterone and its clinical application. (2013) (31)
Value of urologic investigation in a targeted group of women with recurrent urinary tract infections. (1991) (31)
Androgen replacement therapy in aging men with secondary hypogonadism (2001) (31)
Renal oncocytomas: clinical, radiological and histological features. (1980) (31)
Immune reactivity in renal cancer: a sequential study. (1976) (30)
A comparative analysis of rapid urine tests for the diagnosis of upper urinary tract malignancy. (2003) (30)
Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer: a phase II trial. (1982) (30)
Pre-penile arteries are dominant in the regulation of penile vascular resistance in the rat (2000) (29)
Nocturnal penile tumescence recording with stamps: a validity study. (1982) (29)
Androgen deficiency in the aging male. (2003) (29)
The significance of biological variation in the diagnosis of testosterone deficiency, and consideration of the relevance of total, free and bioavailable testosterone determinations. (2010) (28)
BCG: A throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy. (2017) (28)
Immunoprophylaxis of a murine bladder cancer with high dose BCG immunizations. (1982) (27)
Corporeal calibration: a discriminatory test for impotence. (1982) (27)
Adjuvant immunotherapy in superficial bladder cancer. (1978) (26)
Standards, Guidelines and Recommendations of The International Society for The Study of the Aging Male (ISSAM) Investigation, treatment and monitoring of late-onset hypogonadism in males Official Recommendations of ISSAM (2002) (26)
Modified Pereyra bladder neck suspension. (1985) (26)
Yohimbine for treatment of impotence in diabetes. (1981) (26)
Immunotherapy of superficial bladder cancer with BCG (1986) (26)
Hypogonadism and erectile dysfunction: pathophysiological observations and therapeutic outcomes (2003) (26)
Screening assessment of penile tumescence and rigidity. Clinical test of Snap-Gauge. (1987) (25)
Coronary artery bypass graft surgery and its impact on erectile function: a preliminary retrospective study. (1996) (25)
The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate. (1970) (25)
Functional testosterone: Biochemical assessment of hypogonadism in men – Report from a multidisciplinary workshop hosted by the Ontario Society of Clinical Chemists (2007) (24)
Development of adenocarcinoma in transverse colon conduit. (1982) (24)
Silicone gel-filled testicular prosthesis and systemic disease. (1993) (23)
Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9–12 February 2006, Salzburg, Austria (2006) (23)
Evaluation of the urological assessment in impotence: findings with a new diagnostic rating scale. (1984) (22)
Third International Conference on the Management of Erectile Dysfunction: Linking Pathophysiology and Therapeutic Response. (2003) (22)
Nocturnal penile tumescence with stamps: a comparative study under sleep laboratory conditions. (1983) (22)
The prognostic significance of histological grading and pathological staging in carcinoma of the prostate. (1983) (22)
Andropause--a multisystem disease. (2001) (22)
Is testosterone a friend or a foe of the prostate? (2011) (21)
Epididymal lymphoma: an unusual scrotal mass. (1984) (21)
Sub-nanogram analysis of yohimbine and related compounds by high-performance liquid chromatography. (1985) (21)
An uncommon urologic presentation of a supernumerary breast. (1997) (21)
A critical appraisal of accuracy and cost of laboratory methodologies for the diagnosis of hypogonadism: the role of free testosterone assays. (2012) (21)
Immunotherapy of an experimental adenocarcinoma of the prostate. (1995) (21)
Necrotizing fasciitis of the male genitalia (Fournier's gangrene). (1983) (20)
Nephrogenic adenoma of bladder developing after renal transplantation. (1982) (20)
Developmental status of topical therapies for erectile and ejaculatory dysfunction (2000) (19)
Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent. (2008) (19)
A new device for diagnostic screening of nocturnal penile tumescence. (1983) (18)
Erectile Dysfunction: Issues in Current Pharmacotherapy (1998) (18)
Yohimbine in erectile dysfunction: would an orphan drug ever be properly assessed? (2001) (18)
Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. (1996) (17)
Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate. (1985) (17)
Androgen therapy in advanced carcinoma of the prostate. (1971) (17)
Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists. (2013) (16)
Androgens are Fundamental in the Maintenance of Male Sexual Health (2011) (16)
Synchronous independent primary osteosarcoma and adenocarcinoma of kidney. (1983) (15)
Testosterone Deficiency Syndrome: an overview with emphasis on the diagnostic conundrum. (2014) (15)
Communication patterns in patients with erectile dysfunction and their partners. (1994) (15)
Population‐based patterns of prescription androgen use, 1976–2008 (2014) (15)
Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin (2016) (15)
Re: The quality of life during intravesical bacillus Calmette-Guerin therapy. (1996) (15)
SCREENING ASSESSMENT OF PENILE TUMESCENCE AND RIGIDITY (1987) (15)
Chemoimmunoprophylaxis of an experimental bladder cancer with retinoids and Bacillus Calmette Guérin. (1983) (14)
Testosterone replacement: when is there a role? (2000) (14)
Diurnal penile tumescence recording in the etiological diagnosis of erectile dysfunction. (1994) (14)
The mechanisms of continence in the Indiana pouch: a video-urodynamic study. (1990) (14)
Words of wisdom. Re: detection of circulating urothelial cancer cells in the blood using the CellSearch system. (2007) (13)
A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment. (2021) (13)
Intralesional administration of biological response modifiers in the treatment of localized cancer of the prostate: a feasibility study. (1997) (13)
Testosterone and prostate health: debunking myths demands evidence, caution, and good clinical judgment. (2006) (13)
Testosterone treatment for the aging man: The controversy (2004) (12)
Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment - topical versus systemic. (2012) (12)
The andropause: bare facts for urologists (2003) (12)
Response of renal adenocarcinoma to cyclophosphamide. (1975) (12)
Percutaneous aspiration and sclerotherapy for treatment of spermatoceles. (2001) (11)
Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome (2008) (11)
Endocrine causes of impotence (nondiabetes). (2003) (11)
Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent (2008) (11)
First International Conference on the Management of Erectile Dysfunction Overview consensus statement (2000) (11)
An integral view of the neuroendocrine aspects of male sexual dysfunction and aging. (2003) (11)
BCG immunotherapy of metastatic adenocarcinoma of the kidney. (1978) (10)
Treatment of refractory interstitial cystitis (2005) (10)
264: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Carcinoma in Situ of the Urinary Bladder (2004) (10)
From the 19th to the 21st centuries: BCG in the treatment of superficial bladder cancer. (1992) (10)
Prophylaxis and therapy of an experimental bladder cancer with biological response modifiers. (1986) (10)
BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy (2020) (10)
Should hypogonadal men with prostate cancer receive testosterone? (2010) (9)
Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel®, Testosterone 1% gel therapy, in hypogonadal men (2008) (9)
Assessment of cavernous hemangioma of bladder by technetium-99-tagged albumin scan. (1979) (9)
Necrotizing myelopathy associated with renal cell carcinoma. (1983) (8)
Alkalinized intravesical lidocaine to treat interstitial cystitis: absorption kinetics in normal and interstitial cystitis bladders. (2001) (8)
Investigating the STING Pathway to Explain Mechanisms of BCG Failures in Non-Muscle Invasive Bladder Cancer: Prognostic and Therapeutic Implications (2019) (8)
The effect of tumor burden on the modulation of natural killer cell activity. (1984) (7)
Interstitial radiotherapy for localized carcinoma of the prostate. (1983) (7)
The good, the bad, and the unknown of late onset hypogonadism: the urological perspective (2005) (7)
Penile elongation: a method for the screening of impotence. (1983) (7)
Tubing Erosion of an Inflatable Penile Prosthesis Long after Implantation (2014) (6)
Intravesical Therapy of Bladder Cancer: An lmmunotherapy Success Story (1996) (6)
628: Testosterone Values May Alter the Interpretation of Serum PSA Determinations (2004) (6)
Re: Jarow JP et al.: Clinical trial design for the development of new therapies for non-muscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop (Urology 2014;83:262-265). (2014) (6)
Oestrogen therapy and serum cortisol in carcinoma of the prostate. (1975) (6)
Isolation and perfusion of the pudendal vasculature in male rats. (1995) (6)
Pyogenic cyst of adrenal gland. (1983) (6)
Intralesional recombinant α‐interferon for localized prostate cancer: a pilot study with follow‐up of >10 years (2009) (6)
Induction of controlled prostatic tissue necrosis by bacille Calmette-Guérin derivatives (2004) (6)
Androgen replacement therapy in aging men with secondary hypogonadismDraft of Recommendations for endorsement by ISSAM (2002) (6)
Erectile dysfunction: an overview. (2003) (6)
433 EFFICACY AND SAFETY OF MYCOBACTERIAL CELL WALL DNA COMPLEX IN THE TREATMENT OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER AT HIGH RISK OF PROGRESSION AND WHO ARE REFRACTORY TO BCG (2011) (5)
Levodopa in Cancer of the Prostate (1975) (5)
The psychological correlates of psychogenic impotence: A retrospective comparison of psychologenically and organically impotent men (1987) (5)
1650 PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MYCOBACTERIAL CELL WALL-DNA COMPLEX IN THE TREATMENT OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER AT HIGH RISK OF PROGRESSION AND WHO ARE REFRACTORY TO BCG (2011) (5)
Penile sufficiency: an operational definition. (1988) (5)
Testosterone Deficiency Syndrome in Males: Science and Politics (2007) (5)
DISCUSSION PAPER: TREATMENT OF SUPERFICIAL BLADDER CANCER IN MAN * (1976) (5)
Monitoring androgen replacement therapy: testosterone and prostate safety. (2005) (5)
Metastatic renal cell carcinoma regression after nephrectomy and BCG immunotherapy. (1999) (4)
The interpretation of nocturnal penile tumescence monitoring (1995) (4)
Experimental induction ofurothelial metaplasia (1974) (4)
Blunt trauma to renal artery. (1976) (4)
BCG in the treatment of bladder cancer: state of the art. (1989) (4)
Comments on "Considerations for an evidence-based definition of premature ejaculation in the DSM-V". (2010) (4)
This month in Investigative Urology: the production of lymphokines following BCG therapy. (1990) (4)
USE OF TESTOSTERONE IN MEN WITH PROSTATE CANCER AND SUGGESTIONS FOR AN INTERNATIONAL REGISTRY (2011) (4)
Erectile dysfunction: The perspectives of patients and partners on counselling (2002) (4)
Transcutaneous Nitroglycerine Enhances the Quality of Erections in Impotent Men. Results of a Controlled Trial (1987) (4)
Re: Comparison of screening methods in the detection of bladder cancer. (1999) (4)
Re: Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. (1999) (3)
Guest editorial: Bilateral orchidectomy should not be considered an obsolete alternative for metastatic cancer of the prostate. (2012) (3)
Facts and Controversies on the Application of Penile Tumescence and Rigidity: Recording for Erectile Dysfunction (1997) (3)
Androgen replacement therapy in the hypogonadal ageing man (2003) (3)
Words of wisdom. Re: lower testosterone levels predict incident stroke and transient ischemic attack in older men. (2010) (3)
The use of hormonal therapy in "andropause": the pro side. (2013) (3)
A novel approach to premature ejaculation: extracorporeal functional magnetic stimulation. (2009) (3)
282: Mycobacterium Phlei Cell Wall Extract for the Treatment of Superficial Bladder Cancer: Final Results of a Phase 2 Trial (2004) (3)
Enhancement of erectile responses to vasoactive drugs by a variable amplitude oscillation device. (1996) (3)
Men’s Aging and Sexual Disorders: An Update on Diagnosis and Treatment (2005) (2)
Male Infertility and Sexual Dysfunction (1998) (2)
In vivo bupivacaine reduces the in vitro sensitivity of the human vas deferens to phenylephrine. (1986) (2)
Clinical Urology: EditorialEditorial: Impotence (1995) (2)
1783 SAFETY OF INTRAVESICAL MYCOBACTERIAL CELL WALL-DNA COMPLEX GIVEN IMMEDIATELY POSTSURGERY IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (2012) (2)
The diagnosis of impotence (1993) (2)
Melanocortins in sexual function (2004) (2)
Intravesical therapy of bladder cancer : An immunotherapy success story (1996) (2)
Erectile dysfunction and its neuroendocrine correlates: towards an integral perspective (2002) (2)
Diagnosing impotence. (1983) (2)
Testosterone deficiency syndrome and prostate cancer: illustrative annotations for a debate. (2013) (2)
877: A Comparison of the Characteristics of Serum Testosterone Measurements in Men with Late Onset Hypogonadism and Erectile Dysfunction (2004) (2)
Re: Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. I. F. San Francisco, M. M. Regan, W. C. DeWolf and A. F. Olumi, J Urol, 175: 1341-1346, 2006. (2006) (2)
Determining the role of testosterone deficiency in sexual function: the beginning of the end or the end of the beginning? (2014) (1)
Testosterone Replacement in a Man with Intermediate-risk Prostate Cancer. (2017) (1)
Experimental intraprostatic injection of bacillus Calmette-Guerin: a feasibility and safety study. (2005) (1)
Current Status of Noninvasive Pharmacological Therapy for Erectile Dysfunction (1997) (1)
Response to the Letter to the Editor: LOH–pitfalls of an ambiguous abbreviation (2009) (1)
Developments in bladder cancer monitoring. (1998) (1)
Effects of inhibition of steroid biosynthesis on the lymphoid system. (1974) (1)
Clinical Urology: Letter to the EditorIn Reply: Re: Oral Androgens in the Treatment of Hypogonadal Impotent Men (1995) (1)
Erectile dysfunction: clinical drawings for your patients (2001) (1)
Carcinoma prostate - importance of staging by pelvic lymphadenectomy and its use in planning radiation treatment (1978) (1)
COMMENT ON: ORAL ANDROGENS IN THE TREATMENT OF HYPOGONADAL IMPOTENT MEN. AUTHORS' REPLY (1995) (1)
Mycobacterial Cell Wall-DNA Complex (MCC) for the treatment of carcinoma in situ of the bladder: Non-clinical and clinical phase I-II results (2005) (1)
Testosterone deficiency syndrome and cardiovascular health: Looking carefully at the evidence. (2014) (1)
Words of wisdom. Re: hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. (2008) (1)
Commentary on adjunctive use of testosterone gel with sildenafil for erectile dysfunction. (2008) (1)
Experimental induction of urothelial metaplasia. (1974) (1)
Psychogenic impotence: New light on its causation (1983) (1)
Re: Editorial: Data interpretation and integration of new tests into clinical practice. (1998) (1)
Allergy and cancer. (1975) (1)
Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4). (2015) (1)
Future clinical research on the use of BCG for bladder cancer. (1989) (1)
Collaborative Review – Prostate Cancer Testosterone and Prostate Cancer : Revisiting Old Paradigms (2009) (1)
Book review: The most secret quintessence of life. Sex glands and hormones, 1850–1950 (2007) (0)
In Reply: Re (1995) (0)
Sublingual apomorphine dosage forms containing, for use in the treatment of erectile dysfunction (1995) (0)
Developments in the Treatment of Superficial Bladder Cancer (2005) (0)
Taking the first steps in establishing recommendations for testosterone monitoring in men with prostate cancer on androgen-deprivation therapy. (2017) (0)
Re: Open clinical uro-oncology trials in Canada. (2007) (0)
Increased urinary cytokines and apoptotic markers following intravesical administration of a mycobacterial cell-DNA complex (MCC) in patients with carcinoma in situ of the bladder (2001) (0)
Nonsurgical Treatments for Erectile Dysfunction: Oral, Topical, Intracavernous, and Vacuum Devices (1999) (0)
QUEST at 25: An enduring innovation in Canadian urology. (2022) (0)
Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions (2008) (0)
Mycobacterial cell wall complex (MCC) in the treatment of carcinoma in situ of the bladder: Dose escalation study (2003) (0)
838 Phase 1 study with mycobacterial cell wall extract and hyaluronic acid for the intraprostatic treatment of localised prostate cancer (2004) (0)
PCV10 SYSTEMATIC REVIEW OF THE ROLE OF SPECIALIZED PRO-RESOLVING LIPID MEDIATORS IN CARDIOVASCULAR DISEASES (2020) (0)
Female Urology Beyond a Simple Anesthetic Effect: Lidocaine in the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome (2015) (0)
Prostatic microwave therapy: A pilot study for technology assessment (1997) (0)
Administration of Mycobacterium phlei cell wall-nucleic acid complex in the immediate postoperative period for the treatment of non-muscle-invasive bladder cancer. (2016) (0)
Sublingual dosage forms containing apomorphinzur use in the treatment of erectile D ysfunktion. (1995) (0)
Letter: Levodopa in cancer of the prostate. (1975) (0)
Commentary (Morales): BCG Immunotherapy for Transitional-Cell Carcinoma in Situ of the Bladder (1995) (0)
COMMENT ON: COMPARISON OF SCREENING METHODS IN THE DETECTION OF BLADDER CANCER. AUTHORS' REPLY (1999) (0)
Addressing the pressing issues related to testosterone administration to men with prostate cancer. (2016) (0)
Legends in urology. (2008) (0)
Re: elevated bone marrow acid phosphatase: the problem of false positives. (1977) (0)
The failure of cystometry as a diagnostic aid in impotence (1983) (0)
Faculty Opinions recommendation of Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy. (2007) (0)
Testosterone replacement : when is there a role? Discussion (2000) (0)
Conversations in the operating room: history of the development of a promising new compound for the treatment of premature ejaculation (2012) (0)
Sildenafilof its Use in Erectile Dysfunction (1999) (0)
PMS7 THE ROLE OF SPECIALIZED PRO-RESOLVING LIPID MEDIATORS IN THE TREATMENT OF INFLAMMATION CAUSED BY EXERCISING: A SYSTEMATIC REVIEW (2020) (0)
Pharmacological treatment of male sexual dysfunction (1993) (0)
Comment on: Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. Author's reply (2006) (0)
Iconographies supplémentaires de l'article : Beyond a Simple Anesthetic Effect: Lidocaine in the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome (2015) (0)
A Prospective Randomized Placebo-Controlled Multicenter Study on the Efficacy of Intravesical Hyaluronan in Bladder Pain Syndrome/Interstitial Cystitis and Considerations for Designing Future Trials (2019) (0)
COMMENT ON: DATA INTERPRETATION AND INTEGRATION OF NEW TESTS INTO CLINICALPRACTICE. AUTHORS' REPLY (1998) (0)
How to diagnose and treat late-onset hypogonadism (2004) (0)
POD-7.12: Impact of Age on the Ability of Mycobacterial Cell Wall-DNA Complex (MCC) to Induce Urinary Biological Response Markers in Patients with Non-muscle Invasive Bladder Cancer (2008) (0)
Issues in Men’s Health: Hormones, sexual function, and quality of life (2007) (0)
Testosterone and prostate health: Have the paradigms truly shifted? (2020) (0)
Theuseofradioactive phosphorus totreat bone pain inmetastatic carcinoma oftheprostate (1970) (0)
Immune modifiers in the treatment of bladder cancer. (1990) (0)
Central Activation of Erection and Clinical Experience (2005) (0)
468The direct anticancer activity of mycobacterial cell wall-DNA complex (MCC) is not inhibited by anti-MCC antibodies (2005) (0)
717: Mycobacterial Cell Wall-DNA Complex (MCC) Induces IgG Antibody Responses Against MCC and BCG in Patients with CIS of the Bladder (2004) (0)
Impotence : organic factors and management approach (1991) (0)
The medical treatment of impotence: An update (1990) (0)
327Intravesical treatment with mycobacterial cell wall DNA complex (MCC) induces a cytokine profile distinct from BCG (2005) (0)
Hormones and Male Sexual Dysfunction (2004) (0)
Dr. Morales' rebuttal. (2008) (0)
Practical considerations on the restoration of sexual function in the hypogonadal man (2001) (0)
The onset of late life hypogonadism (2008) (0)
POD-7.11: The Effect of the Patient 's Age on Bladder Cancer Immunotherapy Response and Adverse Events: MCC Experience (2008) (0)
Letter to the editor (2002) (0)
Yohimbine in erectile dysfunction: the facts. (2000) (0)
Hormonal Evaluation and Treatment (2006) (0)
Consensus Summary Statement THIRD INTERNATIONAL CONFERENCE ON THE MANAGEMENT OF ERECTILE DYSFUNCTION: LINKING PATHOPHYSIOLOGY AND THERAPEUTIC RESPONSE (2003) (0)
Evolutionofintravesical immunotherapyforbladder cancer:mycobacterialcellwall preparationasapromisingagent (2008) (0)
At a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer. (2020) (0)
Editorial comment. (2014) (0)

This paper list is powered by the following services:

Other Resources About Alvaro Morales

en.wikipedia.org

What Schools Are Affiliated With Alvaro Morales ?

Alvaro Morales is affiliated with the following schools: